Alan H. Bryce

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Rucaparib – drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

  Figshare · 2026-06-18

• Rucaparib – drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

  Future Oncology · 2026-06-18

• Rucaparib – drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

  Figshare · 2026-06-18

• Supplementary Table S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Table S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Data Table S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Data from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Supplementary Data Table S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  2026-06-15

• Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in <i>BRCA</i> -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.

  Journal of Clinical Oncology · 2026-05-27

• PD23-15 SAFETY OF RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND A <i>BRCA</i> MUTATION IN TRITON3

  The Journal of Urology · 2026-04-27

• Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study

  Clinical Cancer Research · 2026-03-25

• Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone

  Cardio-Oncology · 2026-03-20

• Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with <i>BRCA</i> mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.

  Journal of Clinical Oncology · 2026-03-01

• Real-world efficacy and safety of tivozanib in metastatic renal cell carcinoma in a diverse cohort: A multicenter study from the City of Hope enterprise.

  Journal of Clinical Oncology · 2026-03-01

• Efficacy of ¹⁷⁷ Lu-PSMA-617 in neuroendocrine prostate cancer.

  Journal of Clinical Oncology · 2026-03-01

• Bone fractures with androgen pathway inhibitors (ARPi) in patients (pts) with prostate cancer (PCa): A systematic review and network meta-analysis.

  Journal of Clinical Oncology · 2026-03-01